Abstract: The disclosure relates to novel compounds and methods of use of the compounds to maintain the G?i2 protein in its inactive GDP-bound state. The disclosure describes the knockdown or inhibition of G?i2 negatively regulated migration of breast and ovarian cancer cell lines. The novel compounds inhibit the migratory behavior of PC3, DU145 and E006AA prostate cancer cell lines. Specifically, the novel compounds block the activation of G?i2 in oxytocin-stimulated prostate cancer PC3 cells and inhibits the migratory capability of DU145 cells overexpressing constitutively active form of G?i2, under basal and EGF-stimulated conditions.

Abstract: Simultaneous inhibition of the aryl hydrocarbon receptor (AhR) and SRC abolishing androgen receptor (AR) signaling in prostate cancer cells is disclosed herein as an effective treatment for prostate cancer. Provided herein is a therapeutic composition that comprises an aryl hydrocarbon receptor (AhR) antagonist and an SRC inhibitor. In one embodiment, the therapeutic composition further comprises a pharmaceutical excipient. In one embodiment, the AhR antagonist is CH223191 and the SRC inhibitor is PP2 and the therapeutic composition further comprises a pharmaceutical excipient. Methods of using the therapeutic composition to treat prostate cancer or to inhibit prostate cancer cells are also disclosed.

Abstract: Simultaneous inhibition of the aryl hydrocarbon receptor (AhR) and SRC abolishing androgen receptor (AR) signaling in prostate cancer cells is disclosed herein as an effective treatment for prostate cancer. Provided herein is a therapeutic composition that comprises an aryl hydrocarbon receptor (AhR) antagonist and an SRC inhibitor. In one embodiment, the therapeutic composition further comprises a pharmaceutical excipient. In one embodiment, the AhR antagonist is CH223191 and the SRC inhibitor is PP2 and the therapeutic composition further comprises a pharmaceutical excipient. Methods of using the therapeutic composition to treat prostate cancer or to inhibit prostate cancer cells are also disclosed.

Abstract: Simultaneous inhibition of the aryl hydrocarbon receptor (AhR) and SRC abolishing androgen receptor (AR) signaling in prostate cancer cells is disclosed herein as an effective treatment for prostate cancer. Provided herein is a therapeutic composition that comprises an aryl hydrocarbon receptor (AhR) antagonist and an SRC inhibitor. In one embodiment, the therapeutic composition further comprises a pharmaceutical excipient. In one embodiment, the AhR antagonist is CH223191 and the SRC inhibitor is PP2 and the therapeutic composition further comprises a pharmaceutical excipient. Methods of using the therapeutic composition to treat prostate cancer or to inhibit prostate cancer cells are also disclosed.

Abstract: Disclosed are novel organoborane compositions of Formula (I), (II) or (III), wherein R1, R2, R3, R?, R?, n, n?, n?, m, m?, and m? are defined hereinabove. Also disclosed is a method of using said compositions for electrolytic media in lithium rechargeable batteries, including lithium-ion or lithium-air rechargeable batteries. Also disclosed are compositions containing said Formula (I), (II) and (III) compounds with lithium salts, useful as electrolytic media or matrices.

Abstract: The invention provides a polymer composition comprising from 50 wt % to 99.9 wt % polymer, from 0.1 wt % to 10 wt % nanocellulose as a first nucleating agent, and from 0.01 wt % to 5 wt % of a second nucleating agent. In some embodiments, the polymer is polylactide, the first nucleating agent is lignin-containing nanocellulose, and the second nucleating agent is a sulfur-containing, oxygenated aromatic molecule. The oxygenated aromatic molecule may be an aromatic sulfonic acid or salt, such as dimethyl 5-sulfoisophthalate. In other embodiments, the sulfur-containing, oxygenated aromatic molecule is lignosulfonic acid. Other variations provide a polymer composition comprising polymer, lignin-containing nanocellulose as a dispersing agent, and additives selected from nucleating agents, compatibilizers, plasticizers, fillers, antioxidants, colorants, or flame retardants.

Abstract: The invention provides a polymer composition comprising from 50 wt % to 99.9 wt % polymer, from 0.1 wt % to 10 wt % nanocellulose as a first nucleating agent, and from 0.01 wt % to 5 wt % of a second nucleating agent. In some embodiments, the polymer is polylactide, the first nucleating agent is lignin-containing nanocellulose, and the second nucleating agent is a sulfur-containing, oxygenated aromatic molecule. The oxygenated aromatic molecule may be an aromatic sulfonic acid or salt, such as dimethyl 5-sulfoisophthalate. In other embodiments, the sulfur-containing, oxygenated aromatic molecule is lignosulfonic acid. Other variations provide a polymer composition comprising polymer, lignin-containing nanocellulose as a dispersing agent, and additives selected from nucleating agents, compatibilizers, plasticizers, fillers, antioxidants, colorants, or flame retardants.

Abstract: Compositions and methods to treat prostate cancer with the compound camalexin and its structural analogs. Camalexin increases ROS production and decreases the proliferation of prostate cancer cells, especially aggressive prostate cancer cells.

Abstract: Provided are compositions and methods for increasing the production of steroid hormones in testes, ovaries, or adrenal glands in a subject in need thereof. Also provided are compositions and methods for inhibiting proliferation of ovarian, testicular, prostate gland, breast, and liver cancer cells.